Rege Nephro develops therapeutics specifically targeting renal diseases, focusing on improving the quality of life for patients suffering from these conditions. The company's research and development efforts aim to address the unmet medical needs in renal care through innovative treatment solutions.
Funding
$34.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DPFounders
Product
Problem
Chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD) are progressive conditions that can lead to end-stage renal failure, often requiring dialysis or kidney transplantation. Current treatments for these diseases have limitations, either not addressing the underlying causes or having potential side effects, creating a need for more effective and targeted therapies. Existing models for preclinical drug development often fail to translate to human efficacy due to species-specific genetic differences.
Solution
Rege Nephro is developing cell therapies and small molecule drugs to address unmet needs in renal disease treatment. Their iPS cell-derived nephron progenitor cell (iNPC) therapy, RN-032, aims to regenerate damaged kidney tissue and delay or prevent the need for dialysis. For ADPKD, Rege Nephro has developed RN-014, a retinoic acid receptor (RAR) agonist, which has shown promise in preclinical studies using human iPS cell-derived disease models. By using human cell-based models, Rege Nephro seeks to identify and develop therapeutic candidates with a higher likelihood of success in human clinical trials, offering potential for disease modification and improved patient outcomes.
Target Audience
The primary target audience includes patients with chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD), as well as nephrologists and other healthcare providers involved in their care.
Features
- RN-032: iPS cell-derived nephron progenitor cell (iNPC) therapy for chronic kidney disease (CKD)
- RN-032: Aims to regenerate damaged kidney tissue through paracrine effects
- RN-014: Retinoic acid receptor (RAR) agonist for autosomal dominant polycystic kidney disease (ADPKD)
- RN-014: Development informed by human iPS cell-derived ADPKD disease model
- Clinical trials for RN-014 are underway, starting with Phase IIa
- Collaboration with Nikkiso Co., Ltd. for scale-up of iNPC manufacturing